New study results suggest that treatment with Privigen (ImmuneGlobulin Intravenous [Human], 10%Liquid), an intravenous immunoglobulin(IVIG), may lead to improvement in function in patients with chronic inflammatory demyelinating polyneuropathy.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is recommending the expanded use of Pfizer’s Prevnar 13 vaccine.
New research demonstrates how dying or damaged brain cells release debris into the bloodstream and give rise to specific autoantibodies that appear to be reliable biomarkers for early diagnosis of Alzheimer’s and other neurodegenerative diseases.
U.S. Food and Drug Administration researchers have discovered a new mechanism for identifying and understanding drug-related autoimmune reactions.
Researchers at the Scripps ResearchInstitute in La Jolla, Calif., have developed a vaccine that may one day protect people against the addictive effects of nicotine.
As part of the fiscal cliff legislation enacted prior to the end of 2012, $10.5 billion in Medicare overpayments to hospitals will be recovered over the next few years.
The U.S. Department of Health and Human Services has approved $1.5 billion in new Exchange Establishment Grants to ensure states have the required resources to build marketplaces that meet the needs of residents.
The U.S. Department of Health andHuman Services has relaunched its website to attract the 43 million uninsuredAmericans needed to make the healthcare law work when open enrollment in state and federal healthcare exchanges begins in October 2013.
Under the Affordable Care Act’s “10essential health benefits,” individual and small group health plans sold under state-based health insurance exchanges and outside them on the private market will be required to cover pediatric dental services beginning in 2014.
The U.S. Food and Drug Administration has approved Fluarix Quadrivalent to immunize children ages 3 and older and adults against flu virus subtypes A and B.
Danish investigators conducted a trial of adult patients to test whether subcutaneous immunoglobulin therapy is a viable alternative to intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyradiculoneuropathy.
Octapharma USA has started an initiative to make octagam (immune globulin intravenous [human] 5%), a therapy for primary immune deficiency, widely available to covered entities in the 340B Drug Pricing Program.